Advice
Following a full submission
maraviroc (Celsentri) as 150 mg and 300mg tablets is not recommended for use within NHS Scotland in combination with other antiretroviral medicinal products, for treatmentexperienced adult patients infected with only CCR5-tropic HIV-1 detectable.
When added to optimised background therapy, maraviroc was associated with a significant reduction in viral load compared with addition of placebo in heavily pre-treated patients. However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The licence holder has indicated their intention to resubmit.
Download detailed advice76KB (PDF)
Medicine details
- Medicine name:
- maraviroc (Celsentri)
- SMC ID:
- 458/08
- Indication:
- In combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 April 2008